BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20457870)

  • 1. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
    Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
    Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
    Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
    Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
    Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
    PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
    van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
    Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
    Gaspar HB; Parsley KL; Howe S; King D; Gilmour KC; Sinclair J; Brouns G; Schmidt M; Von Kalle C; Barington T; Jakobsen MA; Christensen HO; Al Ghonaium A; White HN; Smith JL; Levinsky RJ; Ali RR; Kinnon C; Thrasher AJ
    Lancet; 2004 Dec 18-31; 364(9452):2181-7. PubMed ID: 15610804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
    Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
    N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
    De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
    Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors.
    Sirven A; Ravet E; Charneau P; Zennou V; Coulombel L; Guétard D; Pflumio F; Dubart-Kupperschmitt A
    Mol Ther; 2001 Apr; 3(4):438-48. PubMed ID: 11319904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
    Thornhill SI; Schambach A; Howe SJ; Ulaganathan M; Grassman E; Williams D; Schiedlmeier B; Sebire NJ; Gaspar HB; Kinnon C; Baum C; Thrasher AJ
    Mol Ther; 2008 Mar; 16(3):590-8. PubMed ID: 18180772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
    van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
    J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
    N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.
    Greene MR; Lockey T; Mehta PK; Kim YS; Eldridge PW; Gray JT; Sorrentino BP
    Hum Gene Ther Methods; 2012 Oct; 23(5):297-308. PubMed ID: 23075105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia.
    Ginn SL; Curtin JA; Kramer B; Smyth CM; Wong M; Kakakios A; McCowage GB; Watson D; Alexander SI; Latham M; Cunningham SC; Zheng M; Hobson L; Rowe PB; Fischer A; Cavazzana-Calvo M; Hacein-Bey-Abina S; Alexander IE
    Med J Aust; 2005 May; 182(9):458-63. PubMed ID: 15865589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.
    Pike-Overzet K; Rodijk M; Ng YY; Baert MR; Lagresle-Peyrou C; Schambach A; Zhang F; Hoeben RC; Hacein-Bey-Abina S; Lankester AC; Bredius RG; Driessen GJ; Thrasher AJ; Baum C; Cavazzana-Calvo M; van Dongen JJ; Staal FJ
    Leukemia; 2011 Sep; 25(9):1471-83. PubMed ID: 21617701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.